Trial Profile
Adding orally disintegrating selegiline (Zelapar) to patients taking dopamine agonists and experiencing complications
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms AtoZ
- 07 Dec 2008 Status changed from recruiting to completed, according to ClinicalTrials.gov.
- 30 Apr 2007 New trial record.